Kornitzer Capital Management’s Novo Nordisk NVO Stock Holding History

Kornitzer Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Sell	23,359 -85,733	-79%	-$3.68M	0.02%	422
2026 Q1	$4.01M	Sell	109,092 -59,053	-35%	-$2.8M	0.09%	220
2025 Q4	$8.56M	Buy	168,145 +9,100	+6%	+$465K	0.18%	125
2025 Q3	$8.83M	Buy	159,045 +2,962	+2%	+$173K	0.18%	131
2025 Q2	$10.8M	Buy	156,083 +225	+0.1%	+$15.3K	0.22%	121
2025 Q1	$10.8M	Buy	155,858 +396	+0.3%	+$32.7K	0.22%	119
2024 Q4	$13.4M	Sell	155,462 -749	-0.5%	-$81K	0.26%	101
2024 Q3	$18.6M	Buy	156,211 +46	+0%	+$6.13K	0.34%	77
2024 Q2	$22.3M	Buy	156,165 +947	+0.6%	+$125K	0.42%	54
2024 Q1	$19.9M	Hold	155,218	–	–	0.37%	68
2023 Q4	$16.1M	Buy	155,218 +1,146	+0.7%	+$113K	0.31%	87
2023 Q3	$14M	Hold	154,072	–	–	0.29%	98
2023 Q2	$12.5M	Hold	154,072	–	–	0.25%	128
2023 Q1	$12.3M	Hold	154,072	–	–	0.24%	127
2022 Q4	$10.4M	Sell	154,072 -70	-0%	-$4.1K	0.21%	148
2022 Q3	$7.68M	Buy	154,142 +2,070	+1%	+$111K	0.16%	198
2022 Q2	$8.47M	Hold	152,072	–	–	0.17%	193
2022 Q1	$8.44M	Buy	152,072 +72	+0%	+$3.69K	0.14%	219
2021 Q4	$8.51M	Hold	152,000	–	–	0.13%	234
2021 Q3	$7.3M	Hold	152,000	–	–	0.11%	249
2021 Q2	$6.37M	Hold	152,000	–	–	0.1%	258
2021 Q1	$5.12M	Sell	152,000 -232	-0.2%	-$8.26K	0.08%	267
2020 Q4	$5.32M	Hold	152,232	–	–	0.09%	265
2020 Q3	$5.29M	Buy	152,232 +232	+0.2%	+$7.73K	0.1%	250
2020 Q2	$4.98M	Buy	152,000 +30,000	+25%	+$957K	0.1%	252
2020 Q1	$3.67M	Buy	122,000 +29,860	+32%	+$889K	0.09%	252
2019 Q4	$2.67M	Buy	92,140 +10,140	+12%	+$281K	0.05%	311
2019 Q3	$2.12M	Buy	+82,000	New	+$2.07M	0.04%	332
2015 Q1	–	Sell	-18,000	Closed	-$381K	–	457
2014 Q4	$381K	Buy	18,000 +3,500	+24%	+$78.2K	﹤0.01%	382
2014 Q3	$345K	Buy	14,500 +1,500	+12%	+$34.5K	﹤0.01%	372
2014 Q2	$300K	Hold	13,000	–	–	﹤0.01%	380
2014 Q1	$297K	Hold	13,000	–	–	﹤0.01%	395
2013 Q4	$240K	Buy	+13,000	New	+$227K	﹤0.01%	400

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

AIIMS

Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Kornitzer Capital Management's NVO Position: Q2 2026 in Review

Kornitzer Capital Management reduced its Novo Nordisk (NVO) stake by 79% in Q2 2026, selling an estimated $3.68M and leaving 23,359 shares worth $1.12M. The position accounts for 0.02% of the portfolio, ranked #422.

Kornitzer Capital Management first reported a position in NVO in Q4 2013 and has held it in 33 quarters since. The position peaked at $22.3M in Q2 2024. 580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Kornitzer Capital Management held 23,359 shares of Novo Nordisk worth $1.12M as of Q2 2026.
Kornitzer Capital Management sold 85,733 Novo Nordisk shares in Q2 2026, an estimated $3.68M.
Novo Nordisk made up 0.02% of Kornitzer Capital Management's portfolio in Q2 2026, its #422 holding.
Kornitzer Capital Management first reported a position in Novo Nordisk in Q4 2013 and has held it in 33 quarters since.
Kornitzer Capital Management's Novo Nordisk position peaked at $22.3M in Q2 2024.
580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Kornitzer Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.